** Shares of drug developer Metsera MTSR.O rise 17.28% to $32.24 premarket
** Co says its experimental weight loss drug, MET-233i, hit up to 8.4% weight loss, on placebo adjusted basis, at 36 days in a small, early-stage trial
** MET-233i, a long-acting injectable monthly amylin analogue, is being developed as a standalone treatment and in combination with another experimental GLP-1 drug MET-097i
** The trial studied MET-233i in 80 participants with overweight or obesity without type 2 diabetes
** Up to last close, stock up 3.7% since it went public in January
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。